EMA Starts New Review of Heart Risks of Non-Selective NSAIDs

The European Medicines Agency said it will start a new review of evidence to determine the heart risks associated with painkilling medicines known as non- selective non-steroidal anti-inflammatory drugs.

The drugs, known as NSAIDs, have been the subject of several European reviews relating to gastrointestinal and cardiovascular safety, the agency said today in a statement on its website. The agency plans to update its 2006 opinion that overall the benefits of NSAIDs outweighed the risks, though the possibility of a small increased chance of heart attacks or strokes couldn’t be ruled out.

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.